The vaccines were tested in diverse groups of people. About 30% of U.S. study participants were Hispanic, African American, Asian or Native American. No safety concerns were identified in these groups, or any others. You can learn more about the trials here:
- Comirnaty (Pfizer) (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine),
- Moderna (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study)
- Johnson & Johnson (https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial)
- Novavax (https://www.novavax.com/insights/diversity-matters-inclusivity-clinical-trials).